- Home
- ABEO vs CLLS Comparison
ABEO vs CLLS Comparison
Compare ABEO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | CLLS |
|---|---|---|
| Founded | 1974 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 384.3M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABEO | CLLS |
|---|---|---|
| Price | $4.30 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $18.75 | $8.50 |
| AVG Volume (30 Days) | ★ 1.4M | 48.3K |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,276.65 | N/A |
| Revenue Next Year | $112.53 | N/A |
| P/E Ratio | $4.29 | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $3.93 | $1.10 |
| 52 Week High | $7.54 | $5.48 |
Technical Indicators
Market Signals| Indicator | ABEO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 35.29 |
| Support Level | $4.00 | $2.49 |
| Resistance Level | $5.62 | $3.22 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 2.44 | 0.00 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.